Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Squamous Cell Lung Cancer

Micro-Abstract The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in squamous cell carcinoma (SCC) and the role of EGFR testing in SCC remain debatable. We retrospectively identified patients with SCC of the lung who had undergone EGFR testing. The EGFR mutatio...

Full description

Saved in:
Bibliographic Details
Published in:Clinical lung cancer 2016-07, Vol.17 (4), p.309-314
Main Authors: Xu, Jianlin, Chu, Tianqing, Jin, Bo, Dong, Xue, Lou, Yuqing, Zhang, Xueyan, Wang, Huiming, Zhong, Hua, Shi, Chunlei, Gu, Aiqing, Xiong, Liwen, Zhao, Yizhuo, Jiang, Liyan, Zhang, Jie, Han, Baohui
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carcinoma, Squamous Cell - drug therapy
Carcinoma, Squamous Cell - mortality
Carcinoma, Squamous Cell - pathology
EGFR
Female
Follow-Up Studies
Hematology, Oncology and Palliative Medicine
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - mortality
Lung Neoplasms - pathology
Male
Middle Aged
Mutation
Mutation - genetics
Neoplasm Staging
NSCLC
Protein Kinase Inhibitors - therapeutic use
Pulmonary/Respiratory
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Receptor, Epidermal Growth Factor - genetics
Retrospective Studies
SCC
Survival Analysis
TKI therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Micro-Abstract The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in squamous cell carcinoma (SCC) and the role of EGFR testing in SCC remain debatable. We retrospectively identified patients with SCC of the lung who had undergone EGFR testing. The EGFR mutation-positive patients had improved overall survival with TKI therapy compared with that of the patients with EGFR wild-type SCC. TKI therapy could be an option for patients with EGFR-mutated SCC.
ISSN:1525-7304
1938-0690
DOI:10.1016/j.cllc.2015.11.009